22848-79-9 Usage
Description
(4beta,5beta,6beta,22S)-1,26-dioxo-5,6:22,26-diepoxyergosta-2,24-diene-4,27-diyl diacetate is a complex steroidal compound derived from ergosterol, featuring a 24-carbon backbone with two epoxy and two acetate groups. It is of interest to researchers in organic chemistry, pharmacology, and medicinal chemistry due to its intricate structure and potential therapeutic applications.
Uses
Used in Pharmaceutical Research:
(4beta,5beta,6beta,22S)-1,26-dioxo-5,6:22,26-diepoxyergosta-2,24-diene-4,27-diyl diacetate is used as a research compound for exploring its biological activities and potential therapeutic effects. Its unique structure allows scientists to investigate its interactions with various biological targets and pathways.
Used as a Precursor in Synthesis:
In the pharmaceutical industry, (4beta,5beta,6beta,22S)-1,26-dioxo-5,6:22,26-diepoxyergosta-2,24-diene-4,27-diyl diacetate serves as a valuable precursor for the synthesis of other bioactive compounds. Its versatile structure can be modified to create new molecules with potential medicinal properties.
Used in Organic Chemistry:
(4beta,5beta,6beta,22S)-1,26-dioxo-5,6:22,26-diepoxyergosta-2,24-diene-4,27-diyl diacetate is utilized in organic chemistry to study the reactions and transformations of complex steroidal structures. This helps chemists develop new synthetic methods and understand the reactivity of similar compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 22848-79-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,8,4 and 8 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 22848-79:
(7*2)+(6*2)+(5*8)+(4*4)+(3*8)+(2*7)+(1*9)=129
129 % 10 = 9
So 22848-79-9 is a valid CAS Registry Number.
22848-79-9Relevant articles and documents
Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers
Llanos, Gabriel G.,Araujo, Liliana M.,Jiménez, Ignacio A.,Moujir, Laila M.,Rodríguez, Jaime,Jiménez, Carlos,Bazzocchi, Isabel L.
, p. 52 - 64 (2017/09/20)
Apoptosis inducers represent an attractive approach for the discovery and development of anticancer agents. Herein, we report on the development by molecular fine tuning of a withaferin A-based library of 63 compounds (2–64), 53 of them reported for the first time. Their antiproliferative evaluation on HeLa, A-549 and MCF-7 human tumor cell lines identified fifteen analogues displaying higher activity (IC50 values ranging 0.3–4.8 μM) than the lead (IC50 values ranging 1.3–10.1 μM) either in lag or log growth phases. SAR analysis revealed that acylation enhances cytotoxicity, suggesting the hydrophobic moiety contributes to the activity, presumably by increasing affinity and/or cell membrane permeability. Further investigation clearly indicated that compounds 3, 11, 12, and 18 induce apoptosis evidenced by chromatin condensation, phosphatidylserine externalization, and caspase-3 activation effects on HeLa cells. The potent capacity to induce apoptosis with concomitant cell loss in G2/M highlights the potential of 27-benzyl analogue (18) as an apoptotic inducer drug candidate.